CDRI’s Efforts to Combat Novel Coronavirus

CDRI’s Efforts to Combat Novel Coronavirus

  • Research Stash
  • News
  • 1.4K

Working on three out of the five verticals formulated by the Council of Scientific and Industrial Research, the Central Drug Research Institute has inked an MoU with King George’s Medical University to sequence the virus strains obtained from COVID-19 patients in Uttar Pradesh.

Initially, the Lucknow-based lab will sequence the virus strains from the samples of a few patients. This activity will be taken up under the first vertical ‘digital and molecular surveillance’.

As of now, eight different variants of the virus are known to be causing the COVID-19 infection. A team has been put into place for analyzing whether changes to the viral sequences, if any, will impact the proposed treatment strategies.

Therapeutics or repurposing of drugs to fight against COVID-19 is the second vertical where CDRI is getting involved. Under this, the researchers are trying to repurpose some already existing drugs that have been used by clinicians.

“One of the fastest ways to get therapeutics to the patient is through repurposing known drugs against COVID-19 infection. Here, CDRI has identified several candidate drugs for repurposing and will develop them further under the collaboration,” said Professor Tapas Kumar, Director, CSIR-CDRI.

The institution has a diverse library of molecules and these have been screened using in silico approaches against a panel of drug targets from SARS-CoV-2 under the third vertical, ‘target-based screening systems. The identified hits will be evaluated in a preliminary drug-target-based screen (primary screen).

“The m-protease, CL-proteinase, RNA-dependent RNA polymerase, Spikeprotein-ACE2 system, and other targets are presently being worked on. Their binding/inhibition will also be evaluated in vitro and in vivo systems with the help of sister laboratories and KGMU,” said Dr. Kumar.

Professor Amita Jain will lead the team of scientists of KGMU, while Professor R. Ravishankar will lead the team of scientists from CSIR-CDRI. Dr. Raj Kamal Tripathi, a virologist at CDRI and an alumnus of KGMU, is leading all the screening related work at CSIR-CDRI. (ISW)

Jyoti Singh

If you liked this article, then please subscribe to our YouTube Channel for the latest Science & Tech news. You can also find us on Twitter & Facebook.

Rate

Therapeutics or repurposing of drugs to fight against COVID-19 is the second vertical where CDRI is getting involved. Under this, the researchers are trying to repurpose some already existing drugs that have been used by clinicians.

“One of the fastest ways to get therapeutics to the patient is through repurposing known drugs against COVID-19 infection. Here, CDRI has identified several candidate drugs for repurposing and will develop them further under the collaboration,” said Professor Tapas Kumar, Director, CSIR-CDRI.

The institution has a diverse library of molecules and these have been screened using in silico approaches against a panel of drug targets from SARS-CoV-2 under the third vertical, ‘target-based screening systems. The identified hits will be evaluated in a preliminary drug-target-based screen (primary screen).

“The m-protease, CL-proteinase, RNA-dependent RNA polymerase, Spikeprotein-ACE2 system, and other targets are presently being worked on. Their binding/inhibition will also be evaluated in vitro and in vivo systems with the help of sister laboratories and KGMU,” said Dr. Kumar.

Professor Amita Jain will lead the team of scientists of KGMU, while Professor R. Ravishankar will lead the team of scientists from CSIR-CDRI. Dr. Raj Kamal Tripathi, a virologist at CDRI and an alumnus of KGMU, is leading all the screening related work at CSIR-CDRI. (ISW)

Jyoti Singh

If you liked this article, then please subscribe to our YouTube Channel for the latest Science & Tech news. You can also find us on Twitter & Facebook.

" }
Vitamin B12 Protects from Thiol Antioxidant Toxicity

Vitamin B12 Protects from Thiol Antioxidant Toxicity

A team of researchers at the Indian Institute of Science Education and Research Mohali has revealed that the thiol reducing agent Dithiothreitol (DTT) causes toxicity

  • News
  • 4.9K
Read more

President Tsai Highlights Progress In Fostering Biomedical Sector

President Tsai Ing-wen said June 26 that the government is committed to fostering Taiwan’s potential-laden biomedical and pharmaceuticals sector through such measures as strengthening local companies’ positions in international markets and bolstering inter ministerial collaboration on industry development initiatives.

  • News
  • 2K
Read more
A Controlled-Release Oral Pill for Kala Azar and Fungal Infections

A Controlled-Release Oral Pill for Kala Azar and Fungal Infections

Researchers have developed a method to produce controlled-release oral tablets for treating fungal infections and kala-azar. The tablets were found to release the drug Amphotericin B in a sustained and controlled manner over a period of 10 days

  • News
  • 1.8K
Read more

Internet is huge! Help us find great content

Newsletter

Never miss a thing! Sign up for our newsletter to stay updated.

About

Research Stash is a curated collection of tools and News for S.T.E.M researchers

Have any questions or want to partner with us? Reach us at hello@researchstash.com

Navigation

Submit